Trial Outcomes & Findings for Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma (NCT NCT02011113)

NCT ID: NCT02011113

Last Updated: 2016-11-01

Results Overview

Myeloma response was defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

36 participants

Primary outcome timeframe

From the first dose until the data cut-off date of 03 Sept 2014; Maximum time in follow-up was 36.0 weeks.

Results posted on

2016-11-01

Participant Flow

All study participants who were on pomalidomide were transferred to the post-marketing study and continued the study treatment when pomalidomide became commercially available.

Treatment phase discontinuation occurred when a participant had confirmed progressive disease, development of unacceptable toxicity, voluntary withdrawal or met other criteria for treatment discontinuation.

Participant milestones

Participant milestones
Measure
Pomalidomide Plus Dexamethasone
Pomalidomide 4 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle. Dexamethasone 40 mg PO once daily on Days 1, 8, 15, 22 of each 28-day cycle for those who are ≤ 75 years of age Dexamethasone 20 mg PO once daily on Days 1, 8, 15, 22 of each 28-day cycle for those who are \> 75 years of age
Overall Study
STARTED
36
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
36

Reasons for withdrawal

Reasons for withdrawal
Measure
Pomalidomide Plus Dexamethasone
Pomalidomide 4 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle. Dexamethasone 40 mg PO once daily on Days 1, 8, 15, 22 of each 28-day cycle for those who are ≤ 75 years of age Dexamethasone 20 mg PO once daily on Days 1, 8, 15, 22 of each 28-day cycle for those who are \> 75 years of age
Overall Study
Adverse Event
4
Overall Study
Disease Progression (DP)
16
Overall Study
Death
1
Overall Study
Insufficient effect of Pomalidomide
1
Overall Study
Investigator's judgement- DP
3
Overall Study
Study terminated by sponsor
11

Baseline Characteristics

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Pomalidomide: 4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle Dexamethasone: 40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
Age, Continuous
64.5 years
n=5 Participants
Age, Customized
≤ 75 Years Old
32 participants
n=5 Participants
Age, Customized
> 75 Years Old
4 participants
n=5 Participants
Sex: Female, Male
Female
20 Participants
n=5 Participants
Sex: Female, Male
Male
16 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
36 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
Race (NIH/OMB)
White
0 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Time from first diagnosis
4.65 years
n=5 Participants
Durie-Salmon Multiple myeloma staging at screening
Stage I
7 participants
n=5 Participants
Durie-Salmon Multiple myeloma staging at screening
Stage II
16 participants
n=5 Participants
Durie-Salmon Multiple myeloma staging at screening
Stage III
13 participants
n=5 Participants
Eastern Cooperative Oncology Group Performance Status] (ECOG)
0 = (Asymptomatic)
17 participants
n=5 Participants
Eastern Cooperative Oncology Group Performance Status] (ECOG)
1 = (Symptomatic but completely ambulatory)
16 participants
n=5 Participants
Eastern Cooperative Oncology Group Performance Status] (ECOG)
2 = (Ambulatory but unable to work)
3 participants
n=5 Participants
Eastern Cooperative Oncology Group Performance Status] (ECOG)
3 = (Limited self-care)
0 participants
n=5 Participants
Eastern Cooperative Oncology Group Performance Status] (ECOG)
4 = (Completely disabled)
0 participants
n=5 Participants
Prior Chemotherapy Regimens
6.0 regimens
n=5 Participants
Prior Stem Cell Transplant for Myeloma
Yes
19 participants
n=5 Participants
Prior Stem Cell Transplant for Myeloma
No
17 participants
n=5 Participants
Durie-Salmon Multiple Myeloma staging at screening
Stage I
7 participants
n=5 Participants
Durie-Salmon Multiple Myeloma staging at screening
Stage II
16 participants
n=5 Participants
Durie-Salmon Multiple Myeloma staging at screening
Stage III
13 participants
n=5 Participants

PRIMARY outcome

Timeframe: From the first dose until the data cut-off date of 03 Sept 2014; Maximum time in follow-up was 36.0 weeks.

Population: Efficacy Evaluable Population includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.

Myeloma response was defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria
25.0 percentage of participants responding
Interval 10.855 to 39.145

PRIMARY outcome

Timeframe: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

Population: Efficacy Evaluable Population (EEP) includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.

Myeloma response was defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date)
41.7 percentage of participants responding
Interval 25.562 to 57.771

SECONDARY outcome

Timeframe: From first dose until the data cut-off date of 03 September 2014; maximum time in follow-up was 36.0 weeks

Population: Efficacy Evaluable Population includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.

Myeloma response was defined as a best overall response of complete response (CR) or partial response (PR) CR is defined as: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria
22.2 percentage of participants responding
Interval 8.642 to 35.803

SECONDARY outcome

Timeframe: From the first dose until the data cut-off date of 03 September 2014. Maximum time on follow-up was 36.0 weeks.

Population: Included participants with at least a PR or better based on Assessment using IMWG criteria.

Time to response was calculated as the time from the first dose to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=9 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Time to Response
4.10 weeks
Interval 4.1 to 24.1

SECONDARY outcome

Timeframe: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

Population: EEP includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.

Myeloma response was defined as a best overall response of complete response (CR) or partial response (PR) CR is defined as: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - \<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to \< 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria (Later Cut-off Date)
38.9 percentage of participants responding
Interval 22.964 to 54.814

SECONDARY outcome

Timeframe: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

Population: Included participants with at least a PR or better based on Assessment using IMWG criteria; EPP includes all participants who meet eligibility criteria, take at least one dose of study medication, and have a baseline and a post-baseline efficacy assessment.

Time to response was calculated as the time from the first dose to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \< 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=15 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Time to Response (Later Cut-off Date)
8.10 weeks
Interval 4.1 to 24.1

SECONDARY outcome

Timeframe: From first dose until the data cut-off date of 03 September 2014; maximum time for follow-up was 36 weeks

Population: Duration of Response was not analyzed as there was insufficient data available at Cycle 2, Day 1 of study treatment. There was limited data evaluated and data were not analyzed.

Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

Population: Efficacy Evaluable Population includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.

Duration of response (calculated for responders only) was defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=15 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Kaplan-Meier Estimates of Duration of Response (Later Cut-off Date)
NA weeks
Interval 20.1 to
The median duration of response based on Kaplan-Meier estimate had not been reached. The upper limit was not calculable because an insufficient number of participants reached the event at the time point for the assessment.

SECONDARY outcome

Timeframe: From the first dose until the data cut-off date of 03 September 2014; maximum time on treatment was 36.0 weeks

Population: Efficacy Evaluable Population includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.

PFS was calculated as the time from the first dosing to the first documented progressive disease, as determined by the investigators based on the IMWG Uniform Response criteria, or death, whichever occurred earlier

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Kaplan-Meier Estimates of Progression-free Survival (PFS)
19.0 weeks
Interval 8.1 to
The upper limit was not calculable because an insufficient number of participants reached the event at the time point for assessment

SECONDARY outcome

Timeframe: From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks

Population: Efficacy Evaluable Population includes all participants who met eligibility criteria, took at least one dose of study medication, and had a baseline and a post-baseline efficacy assessment.

PFS was calculated as the time from the first dosing to the first documented progressive disease, as determined by the investigators based on the IMWG Uniform Response criteria, or death, whichever occurred earlier

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Kaplan-Meier Estimates of PFS (Later Cut-off Date)
32.10 weeks
Interval 9.7 to
The upper limit was not calculable because an insufficient number of participants reached the event at the time point for the assessment.

SECONDARY outcome

Timeframe: From first dose of study drug to final data cut-off date of 25 Sept 2015, maximum duration on treatment was 80.9 weeks

Population: Safety population includes all participants who took at least one dose of study medication.

Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the first treatment of the study medication and within 28 days after the last dose.

Outcome measures

Outcome measures
Measure
Pomalidomide Plus Dexamethasone
n=36 Participants
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
Number of Participants With Adverse Events
Any 1 TEAE
36 participants
Number of Participants With Adverse Events
TEAE related to any study drugs
33 participants
Number of Participants With Adverse Events
TEAE related to Pomalidomide
33 participants
Number of Participants With Adverse Events
TEAE related to Dexamethasone(Dex)
27 participants
Number of Participants With Adverse Events
TEAE with ≥ Grade (GR) 3
33 participants
Number of Participants With Adverse Events
≥ 1TEAE ≥ GR 3 related to any study drug
30 participants
Number of Participants With Adverse Events
TEAE ≥ GR 3 related to Pomalidomide
30 participants
Number of Participants With Adverse Events
TEAE ≥ GR 3 related to Dexamethasone
11 participants
Number of Participants With Adverse Events
≥ 1 serious TEAE
16 participants
Number of Participants With Adverse Events
Serious TEAE related to any study drug
8 participants
Number of Participants With Adverse Events
Serious TEAE related to Pomalidomide
8 participants
Number of Participants With Adverse Events
Serious TEAE related to Dexamethasone
6 participants
Number of Participants With Adverse Events
TEAE leading to stopping of any study drug
5 participants
Number of Participants With Adverse Events
TEAE leading to discontinuation of Pomalidomide
5 participants
Number of Participants With Adverse Events
TEAE leading to discontinuation of Dexamethasone
5 participants
Number of Participants With Adverse Events
Related TEAE leading to stopping of study drug
4 participants
Number of Participants With Adverse Events
Related TEAE leading to stopping of Pomalidomide
4 participants
Number of Participants With Adverse Events
Related TEAE leading to stopping Dexamethasone
4 participants
Number of Participants With Adverse Events
TEAE leading to dose reduction of any study drug
19 participants
Number of Participants With Adverse Events
TEAE leading to dose reduction of Pomalidomide
10 participants
Number of Participants With Adverse Events
TEAE leading to dose reduction of Dexamethasone
15 participants
Number of Participants With Adverse Events
TEA leading to dose interruption of any study drug
20 participants
Number of Participants With Adverse Events
TEAE leading to dose interruption of Pomalidomide
18 participants
Number of Participants With Adverse Events
TEAE leading to dose interruption of Dexamethasone
11 participants
Number of Participants With Adverse Events
Related TEAE leading to dose reduction of any drug
18 participants
Number of Participants With Adverse Events
Related TEAE causing a dose reduction Pomalidomide
10 participants
Number of Participants With Adverse Events
≥1 related TEAE causing a dose reduction: Dex
14 participants
Number of Participants With Adverse Events
Related TEAE leading to interruption of drugs
16 participants
Number of Participants With Adverse Events
Related TEAE causing an interruption Pomalidomide
15 participants
Number of Participants With Adverse Events
Related TEAE causing an interruption to Dex
8 participants
Number of Participants With Adverse Events
TEAE Grade 5
3 participants

Adverse Events

Pomalidomide Plus Dexamethasone

Serious events: 16 serious events
Other events: 36 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Pomalidomide Plus Dexamethasone
n=36 participants at risk
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression or pomalidomide discontinuation for any reason.
Blood and lymphatic system disorders
ANAEMIA
13.9%
5/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Blood and lymphatic system disorders
NEUTROPENIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Blood and lymphatic system disorders
THROMBOCYTOPENIA
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
PNEUMONIA
13.9%
5/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
PNEUMONIA PNEUMOCOCCAL
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
ASTHMA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
HYPOXIA
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
General disorders
MULTI-ORGAN FAILURE
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
General disorders
PYREXIA
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
DECREASED APPETITE
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPONATRAEMIA
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CANCER PAIN
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
CONSTIPATION
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Hepatobiliary disorders
HEPATIC FUNCTION ABNORMAL
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Injury, poisoning and procedural complications
SPINAL COMPRESSION FRACTURE
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Investigations
BLOOD FIBRINOGEN DECREASED
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Musculoskeletal and connective tissue disorders
BACK PAIN
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Renal and urinary disorders
URINARY RETENTION
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Vascular disorders
SHOCK HAEMORRHAGIC
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
BRONCHITIS
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
MENINGITIS
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
PNEUMOCYSTIS JIROVECII PNEUMONIA
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
SEPSIS
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
INTERSTITIAL LUNG DISEASE
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Investigations
C-REACTIVE PROTEIN INCREASED
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Cardiac disorders
CARDIAC FAILURE
2.8%
1/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off

Other adverse events

Other adverse events
Measure
Pomalidomide Plus Dexamethasone
n=36 participants at risk
Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression or pomalidomide discontinuation for any reason.
Blood and lymphatic system disorders
NEUTROPENIA
72.2%
26/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Blood and lymphatic system disorders
THROMBOCYTOPENIA
44.4%
16/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Blood and lymphatic system disorders
ANAEMIA
47.2%
17/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Blood and lymphatic system disorders
LYMPHOPENIA
22.2%
8/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Blood and lymphatic system disorders
LEUKOPENIA
16.7%
6/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
General disorders
PYREXIA
25.0%
9/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
General disorders
OEDEMA PERIPHERAL
19.4%
7/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
General disorders
MALAISE
16.7%
6/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
General disorders
FATIGUE
11.1%
4/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
CONSTIPATION
25.0%
9/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
DIARRHOEA
19.4%
7/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
NAUSEA
19.4%
7/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
HAEMORRHOIDS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
PROCTALGIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Gastrointestinal disorders
VOMITING
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Skin and subcutaneous tissue disorders
RASH
19.4%
7/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Skin and subcutaneous tissue disorders
RASH MACULO-PAPULAR
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Skin and subcutaneous tissue disorders
DECUBITUS ULCER
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
NASOPHARYNGITIS
25.0%
9/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
11.1%
4/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
BRONCHITIS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
PNEUMONIA
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
DECREASED APPETITE
11.1%
4/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPERURICAEMIA
11.1%
4/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPOALBUMINAEMIA
11.1%
4/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPERCALCAEMIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPERGLYCAEMIA
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPOCALCAEMIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPOKALAEMIA
11.1%
4/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPONATRAEMIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
HYPOPHOSPHATAEMIA
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Nervous system disorders
DYSGEUSIA
13.9%
5/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Nervous system disorders
HYPERSOMNIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Nervous system disorders
SOMNOLENCE
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
EPISTAXIS
11.1%
4/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
HYPOXIA
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
DYSPHONIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Respiratory, thoracic and mediastinal disorders
HICCUPS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Psychiatric disorders
ANXIETY
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Investigations
ALANINE AMINOTRANSFERASE INCREASED
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Investigations
ASPARTATE AMINOTRANSFERASE INCREASED
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Investigations
BLOOD ALKALINE PHOSPHATASE INCREASED
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Musculoskeletal and connective tissue disorders
MYALGIA
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Hepatobiliary disorders
HEPATIC FUNCTION ABNORMAL
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
HERPES ZOSTER
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
CYSTITIS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
GASTROENTERITIS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
DIABETES MELLITUS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Psychiatric disorders
INSOMNIA
16.7%
6/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Psychiatric disorders
RESTLESSNESS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Metabolism and nutrition disorders
INCREASED APPETITE
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Nervous system disorders
HEADACHE
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Nervous system disorders
NEUROPATHY PERIPHERAL
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Nervous system disorders
TREMOR
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Investigations
WEIGHT DECREASED
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Investigations
WEIGHT INCREASED
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Vascular disorders
HYPOTENSION
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Endocrine disorders
HYPOTHYROIDISM
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Immune system disorders
HYPOGAMMAGLOBULINAEMIA
5.6%
2/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off
Infections and infestations
Pharyngitis
8.3%
3/36 • From the start of study drug through 28 days after the last dose of study drug. Maximum duration of study treatment was 80.9 weeks; up to 25 September 2015 data cut-off

Additional Information

Anne McClain, Senior Manager

Celgene Corporation

Phone: 888-260-1599

Results disclosure agreements

  • Principal investigator is a sponsor employee Disclosure agreements varied; the Investigators shall not disclose any material/information disclosed by the Sponsor (Celgene KK) with the clinical trial or information obtained by conducting the clinical trial to third parties without Sponsor's prior written approval.
  • Publication restrictions are in place

Restriction type: OTHER